Skip to main content
. 2015 Oct 30;106(11):1582–1589. doi: 10.1111/cas.12813

Figure 2.

Figure 2

Kaplan–Meier plots of the association of the presence of PIK3CA kinase domain mutation (H1047R) of cfDNA with RFS: (a) BCSS; (c) the presence of PIK3CA helical domain mutation (E542K or E544K) of cfDNA with RFS; (b) BCSS; and (d) in the entire cohort. When the presence of PIK3CA kinase and helical domain mutation of cfDNA was defined as either positive or negative, positive cases seemed to have a trend of longer survival than negative ones in the log‐lank test (PIK3CA kinase domain mutation: (a) RFS, P = 0.067, (c) BCSS, P = 0.10 and PIK3CA helical domain mutation; (b) RFS, P = 0.052, (d) BCSS, P = 0.077. BCSS, breast cancer‐specific survival; cfDNA, cell‐free DNA; RFS, relapse‐free survival.